Screening for Obstructive Sleep Apnea in Medical Patients

• Sponsor: Jordan Collaborating Cardiology Group (Other)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT05980936
• Collaborator: (none)
• Enrollment: 500
• Location: 1
• Anticipated Duration (Months): 13.6
• Patients Per Site Per Month: 36.8

Study Details

Study Description

Brief Summary

Obstructive sleep apnea (OSA) is highly prevalent in the general population and is associated with multiple adverse cardiovascular consequences.

Screening for OSA is recommended in those with typical symptoms, such as daytime sleepiness, loud snoring, or abrupt awakenings with gasping or choking. Patients admitted to the general medical wards with these symptoms will be evaluated for the possibility of having OSA.

Condition or Disease	Intervention/Treatment	Phase
Obstructive Sleep Apnea	Other: Screening for obstructive sleep apnea

Detailed Description

Obstructive sleep apnea (OSA) is a disease that is highly prevalent in all communities and is associated with adverse cardiovascular events.

Screening for OSA is recommended in men and women who have the typical symptoms, including snoring, daytime sleepiness, or abrupt awakenings with choking or gasping.

OSA screening is also recommended for those with resistant hypertension, bradyarrhythmias, and atrial fibrillation.

Heart failure patients should also be screened for OSA. It is very important to increase the use of OSA screening especially in patients admitted to the medical floor in tertiary care hospitals. No study has evaluated this topic in the Middle East in the past.

Study Design

• Study Type: Observational
• Anticipated Enrollment: 500 participants
• Observational Model: Case-Only
• Time Perspective: Cross-Sectional
• Official Title: Screening for Obstructive Sleep Apnea in the General Medical Ward in Tertiary Care Centers in the Middle East
• Anticipated Study Start Date: Aug 15, 2023
• Anticipated Primary Completion Date: Aug 15, 2024
• Anticipated Study Completion Date: Oct 1, 2024

Outcome Measures

Primary Outcome Measures

1. Number of Participants who are found to have obstructive sleep apnea [From date of study enrollment until the date of first documented diagnosis of obstructive sleep apnea, assessed up to 4 weeks.]

   Those who are found to have symptoms of OSA will be referred for further evaluation to get the final diagnosis of OSA

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All

Inclusion Criteria:

• Willing to sign an informed consent

• Patient is admitted to the medical ward in a tertiary hospital

Exclusion Criteria:

• Patients known to have obstructive sleep apnea.

• Patients younger than 18 years of age

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Istishari Hospital	Amman		Jordan	11888

Sponsors and Collaborators

• Jordan Collaborating Cardiology Group

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Jordan Collaborating Cardiology Group
• ClinicalTrials.gov Identifier: NCT05980936
• Other Study ID Numbers: IH.OSAScrnng.2023/2
• First Posted: Aug 8, 2023
• Last Update Posted: Aug 8, 2023
• Last Verified: Jul 1, 2023

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Jordan Collaborating Cardiology Group: Obstructive sleep apnea; Symptomatology; Middle East
• Additional relevant MeSH terms: Apnea; Sleep Apnea Syndromes; Sleep Apnea, Obstructive

Study Results

No Results Posted as of Aug 8, 2023